Glenmark Pharmaceuticals Limited (BOM:532296)
India
· Delayed Price · Currency is INR | Market Cap | 462.58B |
| Revenue (ttm) | 134.35B |
| Net Income (ttm) | 10.47B |
| Shares Out | n/a |
| EPS (ttm) | 37.10 |
| PE Ratio | 44.18 |
| Forward PE | 26.83 |
| Dividend | 2.50 (0.15%) |
| Ex-Dividend Date | Sep 13, 2024 |
| Volume | 8,187 |
| Average Volume | 50,874 |
| Open | 1,653.15 |
| Previous Close | 1,653.75 |
| Day's Range | 1,637.60 - 1,664.00 |
| 52-Week Range | 1,199.95 - 1,830.05 |
| Beta | n/a |
| RSI | 74.11 |
| Earnings Date | May 23, 2025 |
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty products, and OTC pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetic, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, drops, and respiratory/MDI/DPI/n... [Read more]
Financial Performance
Financial StatementsNews
Glenmark receives five procedural observations from USFDA after Monroe facility inspection
Glenmark Pharmaceuticals on Wednesday announced that the United States Food & Drug Administration (USFDA) has issued a Form 483 with five procedural observations following a recent inspection at its M...
HSBC maintains buy on Glenmark Pharma, sees Rs 1,720 target; ISB 2001 deal key trigger
HSBC has maintained a buy rating on Glenmark Pharmaceuticals, with a target price of ₹1,720, implying a potential upside of nearly 24% from the current market price of ₹1,389.20. The brokerage acknowl...
Stocks to watch on May 27: CLSA, HSBC, Jefferies issue fresh views on Glenmark, Fusion, Nazara, AB Fashion, IT sector
A series of post-earnings commentary from top brokerages have spotlighted key stocks including Glenmark Pharma, Fusion Microfinance, Nazara Technologies, Brainbees (FirstCry), and Aditya Birla Fashion...
Stocks to watch on brokerages on May 26: Jefferies bullish on NTPC, GMR; mixed views on Ashok Leyland, JSW Steel
On May 26, several prominent stocks are in focus today as brokerages have released updated views and target price revisions for key Indian stocks following Q4 results. Here’s a look at the top calls a...
Stocks to watch today on May 26: Glenmark, JSW Steel, GE Vernova, Ashok Leyland, Balkrishna Industries, NTPC in focus after Q4 results
The markets on 26 May 2025 will react to a slew of Q4FY25 earnings and F&O developments. Investors will track a mix of pharma, auto, energy, and capital goods companies reporting their March quarter r...
Nomura retains ‘Neutral’ call on Glenmark; Q4 results miss and weak domestic performance weigh on outlook
Nomura has kept its ‘Neutral’ stance on Glenmark Pharmaceuticals with a target price of ₹1,500 after the company reported Q4FY25 results below expectations, alongside a significant miss on its full-ye...
Q4 earnings today: JSW Steel, Ashok Leyland, BEML, Glenmark among key firms set to report numbers
The earnings season continues to gain momentum as more than 200 companies are set to announce their financial results for the quarter ended March 2025 today. The list includes several key names across...
Stocks to watch today on May 6: Paras Defence, Fortis, RIL, CAMS, Prataap Snacks, Glenmark, IEX, Indian Hotels in focus
A slew of corporate developments and quarterly earnings results are set to steer investor sentiment in Tuesday’s trade. Here are the top stocks to watch today: Paras Defence and Space Technologies The...
Glenmark, Sun & Zydus recall products in US for 'manufacturing deviations'
India News: NEW DELHI: Drug makers Glenmark, Sun Pharma and Zydus are recalling products in the US for manufacturing issues, the US Food and Drug Administration (.
Glenmark recalls 39 drugs in US under Class-II category, cites expiry as key reason
Shares of Glenmark Pharmaceuticals remained under pressure on Wednesday after the United States Food and Drug Administration (USFDA) classified the recall of 39 drug products from its US subsidiary un...
Glenmark Pharma shares in focus as USFDA classifies recall of 39 drugs from US arm under Class-II
Shares of Glenmark Pharmaceuticals are likely to remain in focus after the US Food and Drug Administration (USFDA) classified the recall of 39 drugs from its US subsidiary under Class-II. The recall w...
Pharma stocks reel under pressure: Biocon plunges 5.64%, IPCA Labs slips 4.67%, Glenmark down 3.56%; Torrent Pharma lone gainer
Pharmaceutical stocks witnessed heavy selling pressure in early trade on Monday, dragged down by broader market weakness amid rising global trade tensions. At 9:28 AM, benchmark indices Sensex and Nif...
Glenmark Pharmaceuticals appoints Anurag Mantri as President; CFO V.S. Mani to retire on May 26
Glenmark Pharmaceuticals Limited has announced a key leadership transition with the appointment of Mr. Anurag Mantri as President (Senior Management Personnel) effective April 7, 2025. The development...
Glenmark Pharma shares gain over 3% as US spares Indian drug exports from 26% reciprocal tariff
Shares of Glenmark Pharmaceuticals rose 3.28% to ₹1,565.15 on April 3 after the U.S. government excluded pharmaceutical products from the newly introduced 26% reciprocal tariff regime. The exemption c...
Glenmark Pharma launches Vancomycin Hydrochloride for injection in the U.S.
Glenmark Pharmaceuticals Inc., USA, has announced the launch of Vancomycin Hydrochloride for Injection USP in 750 mg/vial, 1.25 g/vial, and 1.5 g/vial (Single-dose vial). The product is bioequivalent ...
Glenmark to shut Switzerland-based IGI facility by July 2025
Glenmark Pharmaceuticals Limited has announced that its wholly owned subsidiary, IGI Inc., will cease all CMC development and clinical supplies manufacturing operations at its facility located in La C...
HSBC upgrades Glenmark to ‘Buy’, sees 22% upside in stock price on potential ISB 2001 out-licensing deal, margin expansion visibility
Global brokerage HSBC has upgraded Glenmark Pharmaceuticals to a ‘Buy’ rating from ‘Hold’ and raised the target price to ₹1,785 from ₹1,630, implying a potential upside of around 22%. The upgrade is d...
Stocks to watch today: Ola Electric, Hero MotoCorp, Manappuram Finance, JSW Energy, Hindalco, Glenmark, TVS, Concor, TCS, Paradeep Phosphates and more [March 21, 2025]
Here are the top stocks to watch on March 21, 2025: Ola Electric Mobility Ltd: The company issued a strong clarification dismissing recent media reports about its February 2025 sales data as misleadin...
Glenmark Pharma launches Empagliflozin in India, expands cardiometabolic portfolio
Glenmark Pharmaceuticals has announced the launch of Empagliflozin and its fixed-drug combinations (FDCs) in India, strengthening its presence in the cardiometabolic segment. The new products will be ...
Glenmark Pharma share price in focus after US OTC launch of Polyethylene Glycol 3350
Shares of Glenmark Pharmaceuticals (NSE: GLENMARK) are expected to be in focus today after the company announced the US launch of Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC). ...
Stocks to watch today: AstraZeneca, Glenmark, Aurobindo Pharma, Mankind Pharma, Bayer Crop in pharma updates
The pharmaceutical sector saw a mix of regulatory approvals and tax-related issues. Key Highlights AstraZeneca: Received approval from the Central Drugs Standard Control Organisation to import a lung ...
Pharma Stocks: Glenmark down 2.43%, Divi’s Lab slips 2.10%, Biocon drops 2.57%, Glaxo plunges 3.44%, Nifty down 1.22%
The pharmaceutical sector experienced a broad-based decline, contributing to the overall market weakness as Nifty fell by 1.22% (-275.80 points) to 22,269.25. Glenmark dropped by 2.43%, closing at ₹1,...
Glenmark settles US lawsuit over Generic Zetia and Vytorin for $7 million
Glenmark Pharmaceuticals Ltd. and its subsidiary, Glenmark Pharmaceuticals Inc., USA, recently reached a settlement in ongoing antitrust and consumer protection lawsuits concerning generic Zetia® and ...
Glenmark Pharma shares jump 4% as Q3 revenue jumps 35.1% YoY
Glenmark Pharmaceuticals Ltd shares jumped 4% following the release of its Q3 results. As of 10:14 AM, the shares were trading 3.48% higher at Rs 1,369.15. The company posted a net profit of ₹347.9 cr...
Glenmark Pharmaceuticals launches Latanoprost Ophthalmic Solution, 0.005% in the U.S
Glenmark Pharmaceuticals Inc., USA (Glenmark) has officially launched Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL) in the United States. This FDA-approved treatment is bioequivalent and therap...